Letters New drugs for hyponatraemia

Cost effectiveness of tolvaptan

BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d1947 (Published 29 March 2011) Cite this as: BMJ 2011;342:d1947
  1. Paul Grant, physician
  1. 1Department of Endocrinology, King’s College Hospital, London SE5 9RS, UK
  1. drpaul.grant{at}doctors.org.uk

Amin and Meeran refer to the relative expense of tolvaptan, one of the new vasopressin 2 receptor antagonists.1 They suggest that it has little benefit over existing treatments but fail to mention …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe